The effect of percutaneous coronary revascularization on plasma N-terminal pro-B-type natriuretic peptide levels in stable coronary artery disease

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a clinical study.

This study was conducted to assess the effect of percutaneous coronary revascularization (PCR) on plasma NT-proBNP concentration in patients with chronic stable angina (CSA).

Who Took Part

According to the abstract, 22 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

After stabilization of medications for 8 weeks, resting supine plasma NT-proBNP levels were measured and patients underwent PCR of the involved vessels.

How the Study Was Run

The researchers set it up as a open-label study.

Being open-label, the BNP (Nesiritide) study did not mask who received what.

A time span of 8 weeks appears in the methods.

Eight weeks later, with medications unaltered; plasma NT-proBNP levels were repeated and compared with the baseline levels.

LV systolic and diastolic functions were assessed before and after PCR.

What Was Measured

PubMed files the paper under topics including Angina, Stable, Biomarkers, Coronary Angiography, Coronary Artery Disease, Electrocardiography, Natriuretic Peptide, Brain and Peptide Fragments.

Author keywords: Chronic stable angina, NT-ProBNP and Percutaneous coronary revascularization.

What This Means in Plain Language

The paper is an open-label study of BNP (Nesiritide) in 22 patients over 8 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Indian heart journal), a journal based in India.

More context: the BNP (Nesiritide) compound page, all human trials.